Abstract
Background and Purpose—Substantial evidence now implicates endothelin (ET) in the pathophysiology of cerebrovascular disorders such as the delayed vasospasm associated with subarachnoid hemorrhage and ischemic stroke. We investigated the ET receptor subtypes mediating vasoconstriction in human pial arteries.Methods—ET receptors on human pial and intracerebral arteries were visualized with the use of autoradiography, and the subtypes mediating vasoconstriction were identified by means of wire myography.Results—ET-1 was more potent than ET-3 as a vasoconstrictor, indicating an ETA-mediated effect. Similarly, the selective ETBagonist sarafotoxin S6c had no effect on contractile action at concentrations up to 30 nmol/L. The nonpeptide ETAreceptor antagonistPD156707(3 to 30 nmol/L) caused a parallel rightward shift of the ET-1–induced response, yielding a pA2of 9.2. Consistent with these results,PD156707(30 nmol/L) fully reversed an established constriction in pial arteries induced by 1 nmol/L ET-1, while the selective ETBreceptor antagonist BQ788 (1 μmol/L) had little effect. The calcium channel blocker nimodipine (0.3 to 3 μmol/L) significantly attenuated the maximum response to ET-1 in a concentration-dependent manner without changing potency. In agreement with the functional data, specific binding of [125I]PD151242to ETAreceptors was localized to the smooth muscle layer of pial and intracerebral blood vessels. In contrast, little or no [125I]BQ3020 binding to ETBreceptors was detected.Conclusions—These data indicate an important role for ETAreceptors in ET-1–induced constriction of human pial arteries and suggest that ETAreceptor antagonists may provide additional dilatory benefit in cerebrovascular disorders associated with raised ET levels.

This publication has 40 references indexed in Scilit: